Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Walder%2C+Lydia%22&type=Person&sort=year
/vufind/Search/Results?lookfor=%22Walder%2C+Lydia%22&type=Person&sort=year
Search /vufind/Search2/Results?lookfor=%22Walder%2C+Lydia%22&type=Person&sort=year
PubPharm (11)
1
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer
enthalten in:
Future oncology (London, England)
| 2022
von
Guy, H.
|
Hawkes, C.
|
Walder, L.
| +2
Wird geladen...
2
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective
enthalten in:
Journal of managed care & specialty pharmacy
| 2021
von
Liu, J.
|
Hawkes, C.
|
Walder, L.
| +4
Wird geladen...
3
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer : A TWiST Analysis of the ENGOT-OV16/NOVA Trial
enthalten in:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
| 2019
von
Matulonis, U.
|
Walder, L.
|
Nøttrup, T.
| +18
Wird geladen...
4
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'
enthalten in:
PharmacoEconomics
| 2019
von
Guy, H.
|
Walder, L.
|
Fisher, M.
CommentOn: Pharmacoeconomics. 2019 Mar;37(3):391-405. - PMID 30478649
Wird geladen...
5
Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
enthalten in:
PharmacoEconomics
| 2019
von
Guy, H.
|
Walder, L.
|
Fisher, M.
Wird geladen...
6
Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
enthalten in:
PharmacoEconomics
| 2019
von
Guy, H.
|
Walder, L.
|
Fisher, M.
Wird geladen...
7
Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
enthalten in:
PharmacoEconomics
| 2019
von
Guy, H.
|
Walder, L.
|
Fisher, M.
Wird geladen...
8
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
enthalten in:
PharmacoEconomics
| 2019
von
Guy, H.
|
Walder, L.
|
Fisher, M.
CommentIn: Pharmacoeconomics. 2019 Jul;37(7):963-964. - PMID 31044348
Wird geladen...
9
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
enthalten in:
PharmacoEconomics
| 2018
von
Guy, H.
|
Walder, L.
|
Fisher, M.
Wird geladen...
10
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
enthalten in:
PharmacoEconomics
| 2018
von
Guy, H.
|
Walder, L.
|
Fisher, M.
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
11
Aufsätze
9
E-Artikel
9
E-Ressourcen
2
Gedruckte Aufsätze
Zeitschriftentitel
8
PharmacoEconomics
1
Future oncology (London, England)
1
Journal of clinical oncology : official journal...
1
Journal of managed care & specialty pharmacy
Thema
4
HMC2H89N35
4
Indazoles
4
Journal Article
4
Piperidines
4
Poly(ADP-ribose) Polymerase Inhibitors
4
niraparib
3
Research Support, Non-U.S. Gov't
2
8237F3U7EH
2
Comparative Study
2
Indoles
2
Phthalazines
2
Piperazines
2
WOH1JD9AR8
2
olaparib
2
rucaparib
1
BRCA mutation
1
BRCA1 Protein
1
BRCA1 protein, human
1
BRCA2 Protein
1
BRCA2 protein, human
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2
2020-
9
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
11
Englisch
Haven't found what you're looking for?
Wird geladen...